JPRN-jRCT2080221532未知2 期
Clinical Pharmacological study of Tofogliflozin (CSG452) in Patients with Type 2 Diabetes -Evaluation of influence by degree of kidney function
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Has been diagnosed with type 2 diabetes
- •-normal renal function or mild renal impairment patients
- •-HbA1c (Japanese Diabetes Society [JDS] value) >=6.5% and <10.0%
- •-Body mass index (BMI) >=18.5 kg/m2 and <45.0 kg/m2
排除标准
- •Had the following history and/or complications within 24 weeks of tests for screening test
- •-Acute diabetic complications such as diabetic ketoacidosis or hyperglycemic hyperosmolar coma
- •-Acute coronary disease (acute myocardial infarction, unstable angina, etc.) or stroke
- •-Recurrent genitourinary tract infection, defined as two or more episodes of complicated or uncomplicated cystitis or pyelonephritis
研究者
相似试验
未知
1 期
Clinical pharmacology study of Tofogliflozin in patients with hepatic impairmentType 2 diabetesJPRN-jRCT2080221650Chugai Pharmaceutical Co., Ltd.16
已完成
不适用
Comparison of safety and efficacy of Tofogliflozin and Ipragliflozin in patients with type 2 diabetestype 2 diabetesJPRN-UMIN000037158Minami Osaka hospital24
未知
1 期
Drug-drug interaction study (2) of TofoglifloziJPRN-jRCT2080221710Chugai Pharmaceutical Co., Ltd.87
未知
1 期
Drug-drug interaction study (1) of TofoglifloziType 2 diabetsJPRN-jRCT2080221599Chugai Pharmaceutical Co., Ltd.90
已完成
不适用
Evaluation of Preventive Effect of tofogliflozin on cardiovascular function in type 2 diabetes with cardiovascular diseasestype 2 diabetes with cardiovascular diseaseJPRN-UMIN000018344tofogliflozin study group30